Defendant

Teva Pharmaceuticals, Inc.

2 cases as defendant.

Cases
2
Active
1
1 closed
Filed
2023
Top venue
D. Delaware
1 case

Company profile

Teva Pharmaceuticals, Inc. is the U.S. operating entity of Teva Pharmaceutical Industries Ltd. (NYSE/TASE: TEVA), the Israeli group founded in 1901 and headquartered at 124 Dvora HaNevi'a St., Tel Aviv. Teva is publicly traded and independently owned; its 2024 SEC annual report shows revenue of about $16.5 billion and the company reports roughly 30,000–34,000 employees worldwide. Court filings in the Array case identify Teva Pharmaceutical Industries Ltd. as the affiliated parent.

Teva is one of the world's largest generic-drug manufacturers, selling hundreds of generic prescription products and reporting through three segments: United States, Europe, and International Markets. Its branded/specialty portfolio includes AUSTEDO (deutetrabenazine), AJOVY (fremanezumab), UZEDY (risperidone) and COPAXONE (glatiramer acetate); it also markets biosimilars (e.g., Truxima, Selarsdi), supplies active pharmaceutical ingredients and contract manufacturing through its TAPI business (which it has been restructuring after a failed divestiture attempt), and distributes third-party medicines via its Anda unit.

The tracked litigation posture is that of an operating company defending: 0 plaintiff cases and 3 defendant cases, all Hatch-Waxman ANDA infringement actions under 35 U.S.C. § 271(e), in the District of Delaware and the District of New Jersey — not the Eastern District of Texas or other plaintiff-heavy venues. That is the standard pattern for a generic manufacturer sued by brand owners after filing an ANDA; in the Array matter Teva answered and counterclaimed for invalidity.

The most prominent tracked cases are Array BioPharma, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 1:23-cv-00625, filed June 8, 2023), in which Pfizer-owned Array asserts crystallized-binimetinib patents (U.S. 9,562,016; 9,598,376; 9,980,944) against Teva's binimetinib ANDA and which is related to Array's parallel Alembic/Sandoz suit, and Jazz Pharmaceuticals Ireland Ltd. v. Teva Pharmaceuticals, Inc. (D.N.J., filed March 21, 2023), an oxybate (Xywav/Xyrem) case asserting U.S. 10,195,168 after Teva's February 2023 ANDA notice. The two Jazz entries appear to be duplicate records of the same New Jersey suit; litigation databases list it as terminated in December 2023.

Array BioPharma, Inc. v. Teva Pharmaceuticals, Inc.

settled
Docket:
1:23-cv-00625-GBW
Filed:
2023-06-08
Terminated:
2025-08-01

Hatch-Waxman ANDA litigation brought by Array BioPharma against Teva over Teva's generic binimetinib 15 mg tablets (ANDA No. 217509). The case ended in a stipulated dismissal/settlement after briefing on Teva's stay motion pending appeal of the crystallized binimetinib claim construction from the Alembic/Sandoz litigation. Although U.S. 9,314,464 appeared on the case's USPTO report, the narrative states Array asserted only the three Crystallized Binimetinib Patents (U.S. 9,562,016; 9,598,376; 9,980,944) against Teva, and Teva's Paragraph IV notice did not address the '464 patent.

Jazz Pharmaceuticals Ireland Ltd. v. Teva Pharmaceuticals, Inc.

active
Docket:
2:23-cv-01617
Filed:
2023-03-21

Jazz sued Teva over Teva's ANDA for generic Xywav; the complaint lists the '426 patent among the patents-in-suit. Teva filed invalidity contentions and counterclaims; the case was consolidated with the Lupin actions on Dec. 15, 2023, and remains ongoing with no final judgment on '426 found.